Debt-to-equity of Kalaris Therapeutics, Inc. from 31 Mar 2021 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Kalaris Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2021 to 30 Sep 2025.
  • Kalaris Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 281%.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Kalaris Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 281% +316% 30 Sep 2025
Q2 2025 -199% -457% -177% 30 Jun 2025
Q1 2025 -62% -115% -218% 31 Mar 2025
Q4 2024 -32% -68% -192% 31 Dec 2024
Q3 2024 -35% -60% -239% 30 Sep 2024
Q2 2024 258% +236% +1080% 30 Jun 2024
Q1 2024 53% +30% +136% 31 Mar 2024
Q4 2023 35% +14% +67% 31 Dec 2023
Q3 2023 25% +3% +13% 30 Sep 2023
Q2 2023 22% -1% -3.9% 30 Jun 2023
Q1 2023 22% +5% +26% 31 Mar 2023
Q4 2022 21% +7% +51% 31 Dec 2022
Q3 2022 22% +13% +145% 30 Sep 2022
Q2 2022 23% +17% +271% 30 Jun 2022
Q1 2022 18% +10% +135% 31 Mar 2022
Q4 2021 14% 31 Dec 2021
Q3 2021 9% 30 Sep 2021
Q2 2021 6% 30 Jun 2021
Q1 2021 8% 31 Mar 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.